Report overview

The report presents the company's 2024 progress toward the 100 Days Mission, including the first Phase 2 Lassa vaccine trial and the launch of its first Biosecurity Strategy. It also describes CEPI's response teams being activated for three overlapping outbreaks. The company reports workforce growth to 330 employees.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language
Pages
File size

Standards & Assurance

No standards or assurance data is available for this report.

ESG & Materiality

ESG data

Indicators available in this report:

Employees
Women on the board

No materiality data is available for this report.

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services

Report overview

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language
Pages
File size

Standards & Assurance

No standards or assurance data is available for this report.

ESG & Materiality

ESG data

Indicators available in this report:

Employees
Women on the board

No materiality data is available for this report.

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services

Annual Progress Report

Report overview

Document

Standards & Assurance

ESG & Materiality

ESG data

Build your research dataset.

Annual Progress Report

Report overview

Document

Standards & Assurance

ESG & Materiality

ESG data

Build your research dataset.